4-[5-cyclopropyl-3-(2,6-dichloro-phenyl)-isoxazol-4-ylmethoxy]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid | 1103500-22-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-[5-cyclopropyl-3-(2,6-dichloro-phenyl)-isoxazol-4-ylmethoxy]-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid
• 英文别名: 4-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-ylmethoxy]-3,4,5,6-tetrahydro-2H-[1,2']bipyridine-5'-carboxylic acid；6-[4-[[5-Cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methoxy]-1-piperidinyl]-3-pyridinecarboxylic acid；6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]piperidin-1-yl]pyridine-3-carboxylic acid
• CAS: 1103500-22-6
• 化学式: C₂₄H₂₃Cl₂N₃O₄
• 分子量: 488.37
• InChiKey: GBERCDONFIYCNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  88.7
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• COMPOUNDS AND METHODS FOR MODULATING FXR
  申请人：Genin Michael James

  公开号：US20100152166A1

  公开（公告）日：2010-06-17

  Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.

  公式（I）的化合物：公式（I）其中变量如本文所定义，并且其制药组合物和使用方法被披露为治疗血脂异常和与血脂异常相关的疾病的有用药物。
• TREATING LIVER DISORDERS
  申请人：Terns Pharmaceuticals, Inc.

  公开号：US20210244744A1

  公开（公告）日：2021-08-12

  Provided herein are methods and compositions for treating liver disorders, including without limitation non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient. Accordingly, utilized herein are compounds of formulas (I), (II), etc., as disclosed herein.
• US8153624B2
  申请人：——

  公开号：US8153624B2

  公开（公告）日：2012-04-10